Inventor
Pamela A. Pavco
Inventor
Longmont, CO, US
Overview
Patents· 21 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C12Nprimary
C12NMicroorganisms or enzymes33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
A61KPreparations for medical, dental or toiletry purposes22%
C07HSugars11%
C12YEnzymes5%
C07KPeptides3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
Y02ATechnologies for adaptation to climate change2%
PatentTitleYear
11,001,845Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)202110,913,948RNA interference in dermal and fibrotic indications202110,815,485RNA interference in skin indications202010,662,430RNA interference in ocular indications202010,633,654Modified RNAi polynucleotides and uses thereof202010,184,124RNA interference in ocular indications201910,131,904Modified RNAi polynucleotides and uses thereof20189,963,702RNA interference in dermal and fibrotic indications20189,938,530RNA interference in skin indications20189,340,786'RNA interference in dermal and fibrotic indications'20169,303,259'RNA interference in skin indications'20168,846,894'RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)'20148,664,189'RNA interference in skin indications'20147,176,304'RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)'20077,034,009'Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)'20066,818,447'Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor'20046,566,127'Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor'20036,346,398'Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor'20026,214,621'Conjugates of a particle vector and oligonucleotides, process for their preparation, and pharmaceutical compositions containing them'20015,731,295'Method of reducing stromelysin RNA via ribozymes'19985,612,215'Stromelysin targeted ribozymes'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–2003Patents assigned to RIBOZYME PHARM INC (4)· patent assignee history
1997–1998Based in Layfayette, CO, US· patent location history
2001–2014Based in Lafayette, CO, US· patent location history
2002–2006Patents assigned to CHIRON CORP (3)· patent assignee history
2014–2019Patents assigned to RXI PHARMACEUTICALS CORP (7)· patent assignee history
2014–2018Patents assigned to KAMENS Joanne (3)· patent assignee history
2014–2021Based in Longmont, CO, US· patent location history
2019–2021Patents assigned to PHIO PHARM CORP (6)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| RXI PHARMACEUTICALS CORP | 7 | 2014–2019 |
| PHIO PHARM CORP | 6 | 2019–2021 |
| RIBOZYME PHARM INC | 4 | 1997–2003 |
| CHIRON CORP | 3 | 2002–2006 |
| KAMENS Joanne | 3 | 2014–2018 |
Locations
| Location | Patents | Span |
|---|---|---|
| Longmont, CO, US | 12 | 2014–2021 |
| Lafayette, CO, US | 7 | 2001–2014 |
| Layfayette, CO, US | 2 | 1997–1998 |